Abstract 4774
Background
Recent studies demonstrated profound clinical activity of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients. However, the emergence of resistance limits the clinical benefit inevitably, demanding dissection of its underlying mechanisms. Here, we provide the molecular landscape of osimertinib resistance investigated by clinical sample sequencing and patient-derived cancer models.
Methods
The paired tumor tissue (n = 10) and plasma samples (n = 8) were collected from 12 EGFR-mutant NSCLC patients before and after osimertinib treatment in the ASTRIS trial (NCT02474355). The tissue and plasma DNAs were analyzed by targeted next-generation sequencing (NGS) of 112 cancer-related genes (AZ100 panel). The patient-derived cancer cell lines (PDC) and tumor xenografts (PDTX) were established from osimertinib-treated patients. Osimertinib resistant cell line (PC9-GR/AR) was also established by chronic drug administration. The preclinical resistance models were investigated by whole-exome sequencing (WES) and RNA-seq.
Results
The paired baseline and progression sample analysis identified the emergence of acquired mutations, EGFR C797S (n = 1), KRAS G12D (n = 1), and PIK3CA E545K mutations (n = 2), in the progression samples. One of these progression tissue samples with an acquired PIK3CA mutation also lost EGFR. A preexisting KRAS G12D mutation and PTEN loss were also identified in two patients who showed primary resistance to osimertinib. The WES of osimertinib-resistant PDC revealed amplification of GLI1, CDK4, and CCND1. The osimertinib-resistant PDTXs harboring PIK3CA H1047R mutation and MET amplification were established, and PI3K inhibitors and MET inhibitors will be tested. The RNA-seq analysis showed upregulation of epithelial-mesenchymal transition signatures in PC9-GR/AR cells compared to PC9-GR cells that are potentially related to epigenetic resistance mechanisms.
Conclusions
Our multi-layered molecular analysis of osimertinib-resistant patients’ clinical samples and patient-derived cancer models demonstrates a diverse spectrum of osimertinib resistance mechanisms.
Clinical trial identification
Legal entity responsible for the study
Byoung Chul Cho.
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
J.C. Barrett, D. Stetson, J. Chmielecki, A. Markovets: Employee: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract